诚达药业(301201) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥79,756,481.87, a decrease of 14.85% compared to the same period last year[2] - Net profit attributable to shareholders was ¥15,217,992.56, down 52.19% year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥11,267,685.26, a decline of 43.42% compared to the previous year[2] - Basic earnings per share were ¥0.1004, down 51.19% year-on-year[2] - Total operating revenue for Q3 2024 was ¥243,768,662.64, a decrease of 6.3% compared to ¥260,257,787.65 in the same period last year[15] - Net profit for Q3 2024 was ¥40,536,262.31, down 33.8% from ¥61,275,166.69 in Q3 2023[16] - Total comprehensive income for the period attributable to the parent company was CNY 40,392,784.63, a decrease from CNY 61,184,204.86 in the previous period[17] - Basic and diluted earnings per share for the period were CNY 0.2654, down from CNY 0.3955 in the previous period[17] Cash Flow and Liquidity - Cash flow from operating activities showed a net decrease of 60.44%, totaling ¥57,923,046.82[2] - Net cash flow from operating activities was CNY 57,923,046.82, significantly lower than CNY 146,431,354.93 in the previous period[19] - Cash inflow from operating activities totaled CNY 350,488,064.73, compared to CNY 374,080,173.07 in the previous period[18] - Cash outflow from operating activities increased to CNY 292,565,017.91 from CNY 227,648,818.14 in the previous period[18] - The ending cash and cash equivalents balance was CNY 477,496,249.44, down from CNY 1,413,005,628.92 in the previous period[19] - The company’s cash and cash equivalents decreased by 64.87% to ¥479,133,966.54 due to investments in financial products[5] - Cash and cash equivalents decreased from 1,363,938,914.78 to 479,133,966.54, a decline of approximately 65.9%[12] - The company reported a foreign exchange impact on cash and cash equivalents of CNY 1,807,603.45, compared to CNY 774,702.89 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,395,388,572.08, a decrease of 2.44% from the end of the previous year[2] - The total assets of the company amounted to ¥2,395,388,572.08, a slight decrease from ¥2,455,325,018.15 at the end of the previous quarter[14] - The total liabilities decreased to ¥162,380,153.46 from ¥176,403,059.37, indicating a reduction of 7.9%[14] - The equity attributable to shareholders of the parent company was ¥2,230,686,764.40, down from ¥2,277,123,782.24, a decline of 2.0%[14] - Total current assets decreased from 1,642,866,608.15 to 1,463,203,712.55, a reduction of about 10.9%[12] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,654[8] - The top shareholder, Ge Jianli, holds 27.17% of shares, totaling 42,031,360 shares[8] - The second-largest shareholder, Huang Honglin, owns 12.62% of shares, amounting to 19,528,000 shares[8] - Total restricted shares held by major shareholders is 67,520,000, with no shares released during the period[11] - The company has no preferred shareholders as of the reporting period[10] - The company has a repurchase account holding 3,244,700 shares not listed among the top ten shareholders[9] Research and Development - The company reported an increase in R&D expenses by 87.35%, totaling ¥29,780,273.67 for the first nine months of 2024[6] - Research and development expenses rose significantly to ¥29,780,273.67, compared to ¥15,895,510.73 in the previous year, reflecting a 87.2% increase[15] Investment and Impairment - Investment income for the quarter was ¥23,819,115.33, down from ¥29,434,778.21 in the previous year, a decrease of 19.5%[16] - The company reported a significant increase in credit impairment losses, which reached ¥5,975,640.27 compared to ¥2,287,709.53 last year[16] Financing Activities - The cash flow from financing activities showed a net outflow of ¥85,792,824.41, primarily due to dividend payments and share repurchases[7]